Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, Ji P, Zhang CH, Wang WJ, Lin XD, Li LL, Wei YQ, Yang SY. Yang J, et al. Among authors: zheng rl. J Med Chem. 2012 Dec 13;55(23):10685-99. doi: 10.1021/jm301365e. Epub 2012 Nov 16. J Med Chem. 2012. PMID: 23116168
SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y, Xu Y, Feng S, Luo S, Zheng R, Yang J, Wang L, Zhong L, Yang HY, Wang BL, Yu Y, Liu J, Cao Z, Wang X, Ji P, Wang Z, Chen X, Zhang S, Wei YQ, Yang SY. Pan Y, et al. Mol Cancer Ther. 2012 Apr;11(4):952-62. doi: 10.1158/1535-7163.MCT-11-0679. Epub 2012 Feb 8. Mol Cancer Ther. 2012. PMID: 22319204
Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: synthesis, preliminary structure-activity relationships, and in vitro biological evaluation.
Zeng XX, Zheng RL, Zhou T, He HY, Liu JY, Zheng Y, Tong AP, Xiang ML, Song XR, Yang SY, Yu LT, Wei YQ, Zhao YL, Yang L. Zeng XX, et al. Among authors: zheng rl, zheng y. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6282-5. doi: 10.1016/j.bmcl.2010.08.088. Epub 2010 Aug 21. Bioorg Med Chem Lett. 2010. PMID: 20846862
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.
Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY. Li WW, et al. Among authors: zheng rl. J Med Chem. 2012 Apr 26;55(8):3852-66. doi: 10.1021/jm300042x. Epub 2012 Apr 6. J Med Chem. 2012. PMID: 22452518
(2-Anilino-4-methyl-thia-zol-5-yl)(4-chloro-phen-yl)methanone.
Liu JJ, Zheng RL, Yang SY, Xie YM. Liu JJ, et al. Among authors: zheng rl. Acta Crystallogr Sect E Struct Rep Online. 2012 Jan;68(Pt 1):o161. doi: 10.1107/S1600536811053463. Epub 2011 Dec 17. Acta Crystallogr Sect E Struct Rep Online. 2012. PMID: 22259446 Free PMC article.
110 results